Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614337 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
A Phase 2 study, sponsored by Lumos Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT04614337 is a Phase 2 study that has completed, run by Lumos Pharma. The registered enrollment target is 104 participants.
The verdict
NCT04614337, a Phase 2 study, has completed, sponsored by Lumos Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
Interventions
- DRUG LUM-201
- DRUG rhGH Norditropin® pen (34 µg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-12-31 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614337
The ClinicalTrials.gov registry entry for NCT04614337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumos Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LUM-201 is the first listed.
NCT04614337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04614337 about?
NCT04614337 is a clinical study titled "Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)". This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects likely to respond to therapy with LUM-201.
What is the current status of trial NCT04614337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2020-12-31. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT04614337?
The interventions under investigation include: LUM-201 (DRUG), rhGH Norditropin® pen (34 µg/kg) (DRUG).
Who is sponsoring clinical trial NCT04614337?
This trial is sponsored by Lumos Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.